- 作者：Dae Hyun ParkAuthor Vitae ; Jin Kwon Chung ; schcornea@schmc.ac.kr" class="auth_mail" title="E-mail the corresponding author ; Du Ri Seo ; Sung Jin Lee
- 刊名：American Journal of Ophthalmology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：163
- 期：Complete
- 页码：122-131.e2
- 全文大小：1379 K
Design
Randomized controlled trial.
Methods
setting: Soonchunhyang University Hospital, Seoul, South Korea. study population: In all, 130 eyes of 86 dry eye patients who had undergone cataract surgery between January 2014 and January 2015 were enrolled and randomly divided into a diquafosol group and a sodium hyaluronate group. intervention: The diquafosol group used diquafosol 6 times a day and the hyaluronate group used sodium hyaluronate 6 times a day after cataract surgery. main outcome measures: Evaluations of efficacy were conducted based on an Ocular Surface Disease Index questionnaire, tear breakup time (TBUT), Schirmer I test, corneal fluorescein and conjunctival lissamine green staining scores, serial measurement of ocular higher-order aberrations (HOAs), corneal HOAs, and uncorrected distance visual acuity test. Safety evaluations were based on anterior chamber inflammation and discontinuation of the eye drops.
Results
Objective signs and subjective symptoms were aggravated at 1 week postoperatively and began to recover significantly 4 weeks after surgery. The diquafosol group showed significantly superior TBUT (P < .001), corneal fluorescein (P = .045), and conjunctival staining (P = .001) compared to the sodium hyaluronate group throughout the study period. TBUT (P < .001) and the change in HOAs (P = .018) recovered significantly more quickly in the diquafosol group. The safety evaluations showed no intergroup differences.
Conclusions
Eye drops of 3% diquafosol may be an effective and safe treatment for the management of cataract surgery–induced dry eye aggravation in patients with preexisting dry eye.